KRYS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Krystal Biotech (KRYS) is a strong buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company demonstrates robust financial growth, positive analyst sentiment, and strong pipeline developments, making it a compelling opportunity for long-term gains.
The MACD is negative and contracting (-2.524), RSI is neutral at 40.853, and moving averages are converging, indicating no strong trend. The stock is trading near a key support level (S1: 262.082) and below the pivot (272.847), suggesting a potential entry point for long-term investors.
FDA's RMAT designation for KB707, which accelerates clinical development timelines.
Positive early clinical evidence from the KYANITE-1 study showing significant antitumor activity in advanced NSCLC patients.
Strong financial performance with YoY revenue growth of 16.65% and net income growth of 192%.
Analysts consistently raising price targets, with the latest targets ranging from $306 to $338.
MACD and RSI indicators show no clear bullish momentum in the short term.
Stock trend analysis indicates a 60% chance of a short-term decline (-3.44%) in the next day.
In Q3 2025, Krystal Biotech reported a 16.65% YoY increase in revenue to $97.8M, a 192% YoY increase in net income to $79.37M, and a 192.31% YoY increase in EPS to 2.66. Gross margin improved to 95.64%, up 3.92% YoY, showcasing strong profitability and operational efficiency.
Analysts are overwhelmingly positive on KRYS, with multiple firms raising price targets recently. Goldman Sachs raised its target to $327, Clear Street to $338, and BofA to $318, all maintaining Buy ratings. Analysts cite strong pipeline opportunities, particularly in Vyjuvek growth and KB801's potential in neurotrophic keratitis, as key drivers of optimism.
